ZA201201390B - Pyrazole derivatives which modulate stearoyl-coa desaturase - Google Patents
Pyrazole derivatives which modulate stearoyl-coa desaturaseInfo
- Publication number
- ZA201201390B ZA201201390B ZA2012/01390A ZA201201390A ZA201201390B ZA 201201390 B ZA201201390 B ZA 201201390B ZA 2012/01390 A ZA2012/01390 A ZA 2012/01390A ZA 201201390 A ZA201201390 A ZA 201201390A ZA 201201390 B ZA201201390 B ZA 201201390B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrazole derivatives
- coa desaturase
- stearoyl
- modulate
- modulate stearoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24763409P | 2009-10-01 | 2009-10-01 | |
| PCT/EP2010/064672 WO2011039358A1 (en) | 2009-10-01 | 2010-10-01 | Pyrazole derivatives which modulate stearoyl-coa desaturase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201201390B true ZA201201390B (en) | 2012-10-31 |
Family
ID=43066810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/01390A ZA201201390B (en) | 2009-10-01 | 2012-02-24 | Pyrazole derivatives which modulate stearoyl-coa desaturase |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130011361A1 (enExample) |
| EP (1) | EP2483264A1 (enExample) |
| JP (1) | JP2013506638A (enExample) |
| KR (1) | KR20120080226A (enExample) |
| CN (1) | CN102574841A (enExample) |
| AU (1) | AU2010302577A1 (enExample) |
| BR (1) | BR112012007509A2 (enExample) |
| CA (1) | CA2776294A1 (enExample) |
| CL (1) | CL2012000797A1 (enExample) |
| CO (1) | CO6761294A2 (enExample) |
| CR (1) | CR20120134A (enExample) |
| EA (1) | EA201200545A1 (enExample) |
| EC (1) | ECSP12011837A (enExample) |
| IL (1) | IL218294A0 (enExample) |
| IN (1) | IN2012DN01913A (enExample) |
| MA (1) | MA33693B1 (enExample) |
| MX (1) | MX2012003938A (enExample) |
| PE (1) | PE20121439A1 (enExample) |
| PH (1) | PH12012500648A1 (enExample) |
| SG (1) | SG178869A1 (enExample) |
| TN (1) | TN2012000085A1 (enExample) |
| WO (1) | WO2011039358A1 (enExample) |
| ZA (1) | ZA201201390B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850836A1 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| CN110392833A (zh) | 2017-01-06 | 2019-10-29 | 优曼尼蒂治疗公司 | 治疗神经病症的方法 |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| CN112312913B (zh) | 2018-03-23 | 2024-03-08 | 詹森药业有限公司 | 化合物和其用途 |
| CN113906019A (zh) | 2019-01-24 | 2022-01-07 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000058360A2 (en) | 1999-03-29 | 2000-10-05 | Uutech Limited | Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
| CZ296858B6 (cs) | 1999-09-28 | 2006-07-12 | Bayer Corporation | Agonisté receptoru 3 (R3) hypofyzárního peptidu aktivujícího adenylátcyklázu (PACAP) a jejich farmaceutické pouzití |
| ATE475718T1 (de) | 2000-02-24 | 2010-08-15 | Xenon Pharmaceuticals Inc | Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika |
| US7232662B2 (en) | 2000-09-26 | 2007-06-19 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5 |
| CA2580855A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| JP4958784B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体 |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| RU2009109147A (ru) * | 2006-08-15 | 2010-09-27 | Новартис АГ (CH) | Органические соединения |
| RU2009110254A (ru) * | 2006-08-24 | 2010-09-27 | Новартис АГ (CH) | Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений |
| EP2066664A1 (en) * | 2006-09-22 | 2009-06-10 | Novartis AG | Heterocyclic organic compounds |
| US8068738B2 (en) * | 2007-02-21 | 2011-11-29 | Tte Technology, Inc. | System and method for decoding infra-red (IR) signals |
| MX2010009158A (es) * | 2008-02-20 | 2010-09-24 | Novartis Ag | Inhibidores heterociclicos de estearoil-coa-desaturasa. |
-
2010
- 2010-10-01 BR BR112012007509A patent/BR112012007509A2/pt not_active IP Right Cessation
- 2010-10-01 SG SG2012013066A patent/SG178869A1/en unknown
- 2010-10-01 CA CA2776294A patent/CA2776294A1/en not_active Abandoned
- 2010-10-01 IN IN1913DEN2012 patent/IN2012DN01913A/en unknown
- 2010-10-01 JP JP2012531447A patent/JP2013506638A/ja active Pending
- 2010-10-01 US US13/391,900 patent/US20130011361A1/en not_active Abandoned
- 2010-10-01 EA EA201200545A patent/EA201200545A1/ru unknown
- 2010-10-01 WO PCT/EP2010/064672 patent/WO2011039358A1/en not_active Ceased
- 2010-10-01 KR KR1020127011127A patent/KR20120080226A/ko not_active Ceased
- 2010-10-01 AU AU2010302577A patent/AU2010302577A1/en not_active Abandoned
- 2010-10-01 PH PH1/2012/500648A patent/PH12012500648A1/en unknown
- 2010-10-01 PE PE2012000427A patent/PE20121439A1/es not_active Application Discontinuation
- 2010-10-01 CN CN201080044452XA patent/CN102574841A/zh active Pending
- 2010-10-01 EP EP10761003A patent/EP2483264A1/en not_active Withdrawn
- 2010-10-01 MX MX2012003938A patent/MX2012003938A/es not_active Application Discontinuation
-
2012
- 2012-02-21 TN TNP2012000085A patent/TN2012000085A1/en unknown
- 2012-02-23 IL IL218294A patent/IL218294A0/en unknown
- 2012-02-24 ZA ZA2012/01390A patent/ZA201201390B/en unknown
- 2012-03-20 CR CR20120134A patent/CR20120134A/es unknown
- 2012-03-30 CL CL2012000797A patent/CL2012000797A1/es unknown
- 2012-04-03 CO CO12056222A patent/CO6761294A2/es not_active Application Discontinuation
- 2012-04-26 MA MA34807A patent/MA33693B1/fr unknown
- 2012-04-27 EC ECSP12011837 patent/ECSP12011837A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2483264A1 (en) | 2012-08-08 |
| EA201200545A1 (ru) | 2012-12-28 |
| TN2012000085A1 (en) | 2013-09-19 |
| JP2013506638A (ja) | 2013-02-28 |
| WO2011039358A1 (en) | 2011-04-07 |
| CN102574841A (zh) | 2012-07-11 |
| CA2776294A1 (en) | 2011-04-07 |
| KR20120080226A (ko) | 2012-07-16 |
| CR20120134A (es) | 2012-05-17 |
| MX2012003938A (es) | 2012-08-03 |
| BR112012007509A2 (pt) | 2016-11-22 |
| CO6761294A2 (es) | 2013-09-30 |
| PE20121439A1 (es) | 2012-11-06 |
| CL2012000797A1 (es) | 2013-08-09 |
| MA33693B1 (fr) | 2012-10-01 |
| IL218294A0 (en) | 2012-04-30 |
| SG178869A1 (en) | 2012-04-27 |
| IN2012DN01913A (enExample) | 2015-07-24 |
| US20130011361A1 (en) | 2013-01-10 |
| PH12012500648A1 (en) | 2012-11-12 |
| AU2010302577A1 (en) | 2012-03-15 |
| ECSP12011837A (es) | 2012-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL219628A0 (en) | Imidazolidinedione derivatives | |
| ZA201109214B (en) | Fungicide pyrazole carboxamides derivatives | |
| ZA201200895B (en) | Aminopyrazole derivative | |
| IL214184A0 (en) | Fungicidal pyrazoles | |
| ZA201003125B (en) | Imidazole derivatives | |
| IL206576A0 (en) | Monosebacate of pyrazole derivative | |
| ZA201304282B (en) | Pyrazole derivative | |
| ZA201201390B (en) | Pyrazole derivatives which modulate stearoyl-coa desaturase | |
| PL2391608T3 (pl) | Pochodne N-cykloalkilo-N-bicyklometyleno-karboksyamidów jako środki grzybobójcze | |
| IL207225A0 (en) | Indazole derivatives | |
| IL205505A0 (en) | Inhibitors of stearoyl - coa desaturase | |
| IL213828A0 (en) | Pyridazinone derivatives | |
| IL237728A0 (en) | Hydroxymoyl-heterocyclic fungicides | |
| EP2373313A4 (en) | SUBSTITUTED PYRAZOL COMPOUNDS | |
| SG10201710156RA (en) | 4-methylpyrazole formulations | |
| ZA201107435B (en) | Pyrazole copmpound | |
| IL202586A0 (en) | Dsm enabled dslam | |
| GB0806745D0 (en) | Novel imidazole derivatives | |
| ZA201102049B (en) | Substituted imidazole combinations | |
| GB0806744D0 (en) | Novel pyrazole derivatives | |
| HK1168092A (en) | Pyrazole derivatives which modulate stearoyl-coa desaturase | |
| GB0904315D0 (en) | Novel imidazole derivatives | |
| ZA201105781B (en) | Pyridazinone derivatives | |
| GB0915024D0 (en) | An improved coupler |